Drugs / prostaglandins E2
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 0 | NCT03625518 Comparator | Sep 2018 → Jul 2020 | fetal growth restriction, indomethacin embryofetopathy | Tel-Aviv Sourasky Medical Center | Unknown | No outcome recorded |
| Phase 3 | NCT00815542 Comparator | Jun 2012 | cervix disorder | Meir Medical Center | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | prostaglandins E2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03625518 ↗ |
| Known as | Propess | “prostaglandins E2 - Intravaginal Propess for 24 hours” NCT00815542 ↗ |